Restylane Lidocaine 1x1ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
Restylane with lidocaine is Galderma's original gel and the reference product for NASHA® technology: stabilised hyaluronic acid of non-animal origin, particulate, with minimal cross-linking. With a G′ of 701 Pa and a deformability of barely 7 %, it is a firm, minimally deformable gel, intended for wrinkles in the mid dermis and for lips where definition rather than movement is sought.
- Stabilised HA 20 mg/ml
- Lidocaine 3 mg/ml (0.3 %)
- Technology NASHA®
- Contents 1 syringe × 1.0 ml
- Needles 29G TW ½"
Composition and technology
- Stabilised hyaluronic acid: 20 mg/ml, of non-animal origin (produced by bacterial fermentation), suspended in phosphate buffer solution.
- Lidocaine hydrochloride: 3 mg/ml, included to reduce discomfort during treatment.
- NASHA® technology (Non-Animal Stabilized Hyaluronic Acid): the process preserves the long, natural chains of hyaluronic acid and applies a minimal degree of cross-linking. The result is a particulate, firm gel with little tolerance to deformation — the conceptual opposite of the OBT family.
- Rheological profile: G′ 701 Pa at 0.1 Hz and deformability (xStrain) of 7 %, the lowest value in the entire Restylane range. This rigidity is precisely what allows the definition of edges and contours.
- Note on the name: in several European markets the product is now marketed as Restylane® Classyc™ Lidocaine. It is the same formulation.
Position within the range: NASHA and OBT
The entire Restylane range is built on two different gel technologies. Choosing between them is the first clinical decision of the treatment.
NASHA® (Non-Animal Stabilized Hyaluronic Acid): firm, particulate gels that retain the long hyaluronic acid chains with minimal cross-linking. High resistance and very low tolerance to deformation: projection, definition and structural support in areas that must hold their shape.
OBT™ (Optimal Balance Technology, called XpresHAn Technology™ in the US market): soft, flexible gels with a variable degree of cross-linking. Low to intermediate resistance and high tolerance to deformation: the gel follows the movement of the tissue, so it is intended for dynamic and expressive areas.
| NASHA — firmness and projection | G′ 416–799 Pa · deformability 7–19 % |
|---|---|
| Restylane / Classyc Lidocaine | HA 20 mg/ml · G′ 701 Pa · 7 % — wrinkles in the mid dermis, lips |
| Restylane Lyft Lidocaine | HA 20 mg/ml · G′ 799 Pa · 17 % — cheekbones, mid third of the face, dorsum of the hands |
| Restylane Eyelight | HA 20 mg/ml — infraorbital hollowing, supraperiosteal plane |
| Restylane Skinboosters Vital / Vital Light | HA 20 and 12 mg/ml — skin quality and hydration, without volumetric purpose |
| OBT / XpresHAn — flexibility and expression | G′ 70–271 Pa · deformability 761–1,442 % |
| Restylane Refyne | HA 20 mg/ml · G′ 70 Pa · 1,442 % — moderate wrinkles and folds |
| Restylane Kysse | HA 20 mg/ml · G′ 160 Pa · 908 % — lips, submucosal plane |
| Restylane Volyme | HA 20 mg/ml · G′ 171 Pa · 930 % — malar volume, supraperiosteal or subcutaneous |
| Restylane Defyne | HA 20 mg/ml · G′ 271 Pa · 761 % — severe wrinkles and folds |
The G′ (0.1 Hz) and deformability (xStrain) values come from peer-reviewed literature (J Drugs Dermatol 2024;23(12):1332–1338). Galderma does not publish official rheological values.
Indications and treatment areas
Facial tissue augmentation: correction of wrinkles and lip enhancement.
- Facial wrinkles and folds — mid dermis
- Lips — volume and definition of the vermilion border
- Mid third of the face and jawline in deeper planes, where tissue support is adequate
Technique and treatment protocol
- Injection plane: mid dermis for facial wrinkles; submucosal plane in the lips; subcutaneous or supraperiosteal plane in the mid third of the face and the jawline.
- Needles: 29G thin wall (TW) or 30G, ½". Blunt cannulas of 27–28G may be used as an alternative.
- Technique: linear retrograde threading or serial puncture, with low, constant pressure. Because of its particulate, firm character, the NASHA gel is deposited more locally and requires less shaping massage than an OBT gel.
- Prior aspiration in accordance with standard clinical protocol to minimise vascular risk.
- Avoid superficial injection: it can produce contour irregularities or bluish discoloration.
Technical data
| Manufacturer | Q-Med AB (Galderma) — Seminariegatan 21, SE-752 28 Uppsala, Sweden |
|---|---|
| Active substance | Stabilised hyaluronic acid 20 mg/ml, non-animal origin |
| Anaesthetic | Lidocaine hydrochloride 3 mg/ml |
| Technology | NASHA® |
| Vehicle | Phosphate buffer solution |
| Rheology | G′ 701 Pa · deformability 7 % |
| Presentation | 1 glass syringe of 1.0 ml |
| Needles | 29G TW ½" or 30G ½" (alternative: 27–28G blunt cannula) |
| Application plane | Mid dermis; submucosal in the lips |
| Sterilisation | Moist heat (syringe contents) / ethylene oxide (needles) |
| Classification | CE-marked medical device (MDR 2017/745) |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: up to 25 °C. Protect from freezing and from sunlight. No refrigeration required.
- Do not use after the expiry date shown on the pack.
- Single-use product. Do not reuse or re-sterilise.
- The pack contains: 1 glass syringe of 1.0 ml, sterile needle, instructions for use and traceability labels for the patient record.
Contraindications and warnings
Contraindications (Galderma instructions for use): known hypersensitivity to streptococcal proteins or to any component of the product; history of severe allergies or of an anaphylactic reaction; hypersensitivity to lidocaine or to amide-type local anaesthetics; porphyria; active skin inflammation or infection in the area to be treated.
Precautions and individual assessment: coagulation disorders or anticoagulant or antiplatelet therapy (increased risk of haematoma and bleeding at the puncture site); history of hypertrophic or keloid scarring; autoimmune disease; presence of permanent implants in the area.
Warnings: do not inject intravascularly or intramuscularly. Intravascular injection can cause embolisation, vascular occlusion, ischaemia, skin necrosis, visual disturbance, blindness or stroke. Aspiration before injecting and low, constant injection pressure are recommended. Do not mix the gel with other products.
Always consult the instructions for use included in the pack before application.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the manufacturer's official documentation (Restylane® / Restylane® Classyc™ Lidocaine instructions for use, Q-Med AB / Galderma). This data sheet does not replace the instructions for use accompanying the product.